AI Summary
✦ ClarthaLarsen & Toubro is an engineering, procurement, and construction company serving India and international markets. Infrastructure Projects drives building, transport, heavy civil, transmission, renewables, water, and minerals construction. Energy Projects adds clean energy, oil and gas, refineries, petrochemicals, and offshore wind EPC. Hi-Tech Manufacturing supports specialized industrial production, while management expects its drone-focused unit to triple revenue over five years. Revenue grew 11.8% year-on-year, while profit increased 7%, indicating stable margins but slower earnings conversion. ROE is unavailable, and debt-to-equity of 97.64 implies substantial leverage that can amplify financial risk and affect shareholder returns. At 33.7 times earnings, the shares appear rich relative to 11.8% revenue growth and 7% profit growth. Positive sentiment may persist, but valuation leaves limited room for execution delays, project-cost inflation, or leverage-related pressure.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 30 analysts
Fundamentals
Fundamentals institutional score is 82 using growth durability 81.6.
Valuation
Valuation institutional score is 56 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 64 using mean target upside 10.3%; dispersion penalty 13.4; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 75 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 12 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and technical structure provide support.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 14.4% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.47). Confidence: 90%.
Live forward EPS implies next-12-month EPS of ₹180.24. Applying the stock's normalized valuation corridor produces a fair range of ₹5,066.55 to ₹5,652.33, with base value near ₹5,304.46 (+30.0% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹180.24
Forward P/E
22.6x
Base Fair Value
₹5,304.46
Fair Range
₹5,066.55 - ₹5,652.33
Upside To Base
+30.0%
Estimate Source
Live forward EPS
Growth Estimate
+14.0%
5Y Average
24.40
Current
33.67
Overvalued
31.36
Undervalued
28.11
5Y Average
13.04
Current
18.11
Overvalued
16.10
Undervalued
8.90
5Y Average
5.22
Current
5.14
Overvalued
6.01
Undervalued
4.44
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.2x Undervalued | -38% vs avg | -2.7% |
TORRENT PHARMACEUTICALS L TORNTPHARMPharmaceuticals | +54.8% | 13.9% | 78.7x Premium | +38% vs avg | +36.2% |
LARSEN & TOUBRO LTD. trades at a discount (33.9x vs peer avg 57.0x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include CIPLA LTD, TORRENT PHARMACEUTICALS L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹36.02K CrJun 2026Latest net profit
₹4.46K CrJun 2026Latest EPS
₹32.38Jun 2026Net margin
5.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 26,931 | 28,151 | 31,601 | 39,551 | 30,277 | 34,919 | 34,984 | 42,329 | 33,471 | 35,116 | 37,903 | 47,191 | 36,024 |
| Expenses + | 25,057 | 26,230 | 29,142 | 36,063 | 28,281 | 31,967 | 32,101 | 38,571 | 31,080 | 32,796 | 34,739 | 42,500 | 34,109 |
| Operating Profit | 1,873 | 1,921 | 2,459 | 3,488 | 1,996 | 2,952 | 2,883 | 3,758 | 2,391 | 2,320 | 3,164 | 4,691 | 1,915 |
| OPM % | 7% | 7% | 8% | 9% | 7% | 8% | 8% | 9% | 7% | 7% | 8% | 10% | 5% |
| Other Income + | 1,256 | 2,236 | 1,226 | 1,069 | 2,446 | 831 | 1,195 | 1,671 | 2,606 | -4,339 | 1,067 | 903 | 4,094 |
| Interest | 547 | 584 | 630 | 644 | 567 | 583 | 543 | 503 | 474 | 476 | 351 | 374 | 352 |
| Depreciation | 379 | 416 | 438 | 519 | 481 | 505 | 489 | 487 | 483 | 486 | 496 | 521 | 477 |
| Profit before tax | 2,204 | 3,157 | 2,616 | 3,393 | 3,394 | 2,695 | 3,047 | 4,439 | 4,040 | -2,982 | 3,385 | 4,698 | 5,180 |
| Tax % | 19% | 14% | 18% | 20% | 13% | 26% | 21% | 21% | 14% | 20% | 16% | 24% | 14% |
| Net Profit + | 1,792 | 2,710 | 2,136 | 2,715 | 2,969 | 1,988 | 2,404 | 3,509 | 3,485 | -3,591 | 2,832 | 3,561 | 4,455 |
| EPS in Rs | 12.75 | 19.72 | 15.54 | 19.75 | 21.60 | 14.46 | 17.49 | 25.52 | 25.34 | -26.11 | 20.59 | 25.89 | 32.38 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation